Lupin Introduces Doxycycline for Injection USP in US Market
Overview
Global pharma major Lupin Limited (Lupin) announced the launch of doxycycline for injection USP, 100 mg/Vial (single-dose vial) in the United States, post approvals from the United States Food and Drug Administration (FDA).
Doxycycline Injection USP
Doxycycline for injection USP is a generic equivalent of Vibramycin for injection, 100 mg/Vial of Pfizer Inc., indicated to reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline and other antibacterial drugs.
Doxycycline for injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Annual Sale
Doxycycline for injection USP had an estimated annual sale of USD 48 million in the US (IQVIA MAT April 2024).
Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!